- GI innovation·Merck signed MOU to develop new drugs
- by Nho, Byung Chul Nov 12, 2021 05:54am
- GI innovation announced on the 10th that it has signed an MOU with Merck for the manufacture and development of new biopharmaceuticals. This is the first time Merck, which has maintained cooperative relationships with CDMO (Consignment Production and Development) companies such as Samsung Biologics and Binex, has cooperated with Biotech i
- Company
- GX-17, aimed at treating COVID-19, resumes clinical trials
- by Kim, Jin-Gu Nov 12, 2021 05:54am
- Genexine's new anticancer drug candidate GX-I7, which had shown potential as a treatment for COVID-19, will launch a new clinical trial for anticancer drugs. On the 10th, the MFDS approved phase 2 clinical trials of Bevacizumab and Genexine GX-I7 in recurrent glioblastoma. Bevacizumab is the active ingredient of Roche's target anticancer
- Company
- Will BMS's 'Revlimid' be reimbursed as RVd therapy?
- by Eo, Yun-Ho Nov 11, 2021 06:01am
- Whether the multiple myeloma treatment ‘Revlimid’ will succeed in expanding reimbursement to its use in RVd therapy is gaining attention. According to industry sources, reimbursement of Revlimid (lenalidomide) for RVd therapy (Lenalidomide + bortezomib + dexamethasone) passed the Health Insurance Review and Assessment Services’ Cancer
- Product
- Claiming a more expensive drug than a generic
- by Kim JiEun Nov 11, 2021 06:00am
- Pharmacist A, who did not give a follow-up notice of general submission and charged for a drug that was more expensive than an alternative drug, filed a lawsuit claiming that it was an unfair disposition, but the court refused to accept it. The Seoul Northern District Court recently dismissed a claim filed by pharmacist A against the NHIS
- Policy
- Controversy rise over standards used in pricing negotiations
- by Moon, sung-ho Nov 11, 2021 06:00am
- “It may seem cruel for the smaller pharmaceutical companies, but it is important.” The National Health Insurance Services is expected to consider the ‘marketing and sales’ ability of pharmaceutical companies as a major criterion in estimating the ‘expected claims amount’ of the companies, which is an essential part in drug pricing negot
- Company
- What do scholars refer to as effective tx for myeloma?
- by Nov 11, 2021 06:00am
- With the release of various new drugs over the past decade, treatment results for multiple myeloma have been gradually improving. This is because as options vary, opportunities for "customized treatment" to select drugs depending on patients expand. Medical staff's attention is focused on which patients should be used to maximize the effec
- Policy
- RWD & RWE will be important means of use in post-evaluation
- by Kim, Jung-Ju Nov 11, 2021 06:00am
- Limited replacement is appropriate as a means of supplementing proven RC The quality of the site, which will be the standard, such as standardization of medical records at hospitals where data will be calculated. The task of government insurance authorities and the private sector is to increase patient access to very expensive and innov
- Policy
- The MFDS consulted on Expedite Approval of COVID-19 PO
- by Lee, Tak-Sun Nov 10, 2021 05:55am
- The MFDS announced that it is conducting consultations with the company for rapid domestic approval on overseas developed COVID-19 oral treatments on the verge of commercialization. In the case of Molnupiravir, an oral treatment for MSD, the government plans to gradually introduce 404,000 people through a pre-purchase contract in February
- Opinion
- [Reporter’s View] Verify the oral COVID-19 treatments
- by Lee, Tak-Sun Nov 10, 2021 05:55am
- Following COVID-19 vaccines, oral COVID-19 treatments are also expected to enter the market soon as the government plans to phase in 404,000 courses of COVID-19 oral antivirals from next February. If oral treatments for COVID-19 are introduced, Korea will have laid the groundwork for managing the COVID-19 virus like influenza. Also, c
- Company
- Expectations rise for Rinvoq in treating severe AD
- by Nov 10, 2021 05:55am
- A second JAK inhibitor has been introduced to the field of moderate-to-severe atopic dermatitis treatment. Abbvie’s ‘Rinvoq (upadacitinib),’ with its double advantage in improved convenience and effect, is heralding new change in the field of AD treatment. Rinvoq was additionally approved for the atopic dermatitis indication on the 6th
